Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-03-26 English
Communiqué de presse : La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate event: the US FDA granting Fast Track designation to Sanofi's mRNA vaccine candidate for Chlamydia infections. It includes quotes from management, details about upcoming clinical trials, and standard sections for media/investor relations and forward-looking statements. This format is characteristic of an initial announcement of significant corporate news or a regulatory milestone, which aligns best with the 'Earnings Release' (ER) category if it were financial results, but since it is a specific regulatory/development update presented as a press release, it fits the general category for timely corporate announcements. Given the options, this is a high-impact, non-financial-results announcement. It is not a full report (10-K, IR), a presentation (IP), or a management discussion (MDA). It is a press release announcing a regulatory/development event. In the absence of a specific 'Press Release' code, the closest fit for a significant, timely, non-financial announcement that isn't a formal filing or a call transcript is often categorized under 'Regulatory Filings' (RNS) as a general regulatory announcement, or sometimes grouped with 'Earnings Release' (ER) if the database uses ER broadly for period updates. However, since this is a specific regulatory action (Fast Track designation) and not a financial performance summary, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing a regulatory event that doesn't fit other specific categories like DIV, CAP, or TAR. Given the context of FDA action, RNS is the best fit as a general regulatory announcement/press release.
2025-03-26 French
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a specific corporate event: the US FDA granting fast track designation to a Sanofi vaccine candidate. It contains quotes from R&D leadership, details about the clinical trial plans, and standard sections for Media Relations and Investor Relations contacts, concluding with forward-looking statements typical of such announcements. This format strongly indicates an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive financial report (like 10-K or IR) but rather a targeted announcement of a significant development (FDA designation), it fits best under the 'Earnings Release' category, which often encompasses major operational or regulatory milestones announced via press release, or the broader 'Regulatory Filings' (RNS). Given the options, 'ER' is often used for initial announcements of key operational/pipeline news, even if not strictly quarterly earnings. However, since this is a specific regulatory/clinical milestone announcement rather than financial results, 'RNS' (Regulatory Filings - general regulatory announcements) is a safer and more accurate fallback for non-financial, non-meeting related press releases that don't fit other specific categories like M&A (TAR) or Capital Changes (CAP). I will classify it as RNS as it is a general regulatory/operational announcement.
2025-03-26 English
Communiqué de presse : Examen prioritaire accordé aux États-Unis à la soumission réglementaire relative au tolebrutinib pour le traitement de la sclérose en plaques
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces that the US FDA is granting Priority Review to a regulatory submission for the drug tolebrutinib for Multiple Sclerosis (MS). It details clinical trial results (HERCULES, GEMINI 1 & 2) and provides forward-looking statements and contact information. This format—a formal announcement of a significant regulatory/clinical event, often released to the public and investors simultaneously—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing a regulatory milestone (FDA review) and clinical data, it is not a full financial report (10-K, IR) or a transcript (CT). Given the focus on a specific regulatory action and clinical data summary, it aligns best with an Earnings Release (ER) which often includes key operational/pipeline updates, or RNS as a general regulatory announcement. However, ERs are typically tied to financial periods. This document is a specific, non-periodic announcement about drug development/regulatory status. Therefore, the most appropriate general category for a non-standard, significant corporate announcement that isn't a formal financial report or a specific management/governance update is Regulatory Filings (RNS), as it is a public disclosure of a regulatory event. If 'ER' is interpreted broadly to include major pipeline updates, it could fit, but RNS is the safer fallback for specific regulatory news not covered elsewhere.
2025-03-25 French
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# **Press Release**' and announces a significant regulatory event: the FDA accepting the regulatory submission for tolebrutinib for priority review. It contains key financial/corporate communication elements like contact information for Media Relations and Investor Relations, and a standard 'Sanofi forward-looking statement' section typical of such announcements. This format and content strongly indicate an initial public announcement of a material event, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a press release announcing corporate news. Since the core topic is a regulatory submission acceptance, and it is presented as a 'Press Release' rather than a formal regulatory filing (like 10-K or IR), it functions as an immediate public disclosure. Given the options, 'ER' (Earnings Release) is often used for major company news announcements when a more specific category like 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) doesn't fit. However, this is specifically about regulatory progress, not earnings. The closest fit among the provided options for a general, time-sensitive corporate announcement that isn't a formal report or a specific transaction notice is often the 'ER' category when used broadly for major news, or 'RNS' (Regulatory Filings) as a fallback. Since it is a press release announcing a regulatory milestone, and not a formal SEC filing document itself, 'RNS' (Regulatory Filings/General Regulatory Announcements) is the most appropriate category for a non-financial, non-legal, non-management change announcement that is being disseminated publicly via press release.
2025-03-25 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 99% confidence The document title is "Disclosure of trading in own shares". The content details the purchase of Sanofi's own shares over a specific period (17 March 2025 to 21 March 2025), including volume, price, and broker information. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. This matches Filing Type Code POS (Transaction in Own Shares). The document is a detailed report, not an announcement of a report, so the RPA/RNS fallback rule does not apply.
2025-03-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.